News
Our company and people have been featured in major publications around the world
This is the first FDA-cleared product for both detection and diagnosis (CADe/x) of thyroid ultrasound. See-Mode differentiates its thyroid product with the level of automation that it offers, including automatic detection and characterization of thyroid nodules without manual user input, while enabling the clinicians to review and amend the AI outputs.
“Receiving approval from Health Canada is a significant step forward for us at See-Mode, which demonstrates the applicability of our software beyond the vascular studies we currently"
"Receiving our first FDA clearance is a huge step for us at See-Mode, which demonstrates the strength of the product we have built and the robustness of our approach in running clinical studies"
"Since See-Mode's inception, we have seen that clinicians are increasingly looking for ways to speed up their workflow while improving patient care. Thus, we are proud that AVA has obtained CE Mark and TGA approval – on top of the earlier clearances from FDA and HSA – to help with analysis and reporting of vascular studies"